Drug Trial Radar · NCT00987441
Epidural Labor Analgesia and Infant Neurobehavior
Last checked: Nov 20, 2026Latest source record: Jul 27, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
Sep 2009
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 1, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 19 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Infant neurobehavior alteration is predictor of later intelligence development. Many factors would influence or are associated with infant neurobehavior, of which exist or appear during perinatal period. Neuraxial, especially epidural, analgesia to date is the most effective method in relieving labor pain. Although previous studies showed that opioid used in epidural analgesia for labor pain can affect newborn neurobehavior negatively in a dose-escalation associated manner, whether epidural analgesia itself would produce unpredictable effect on newborn neurobehavior is still unknown. Hereby the investigators designed this trial to investigate the hypothesis that epidural analgesia for labor pain control itself would not produce negative effect on infant neurobehavior.
Conditions
- Labor Pain
Interventions
Ropivacaine and sufentanilDrug
Ropivacaine 0.125% plus sufentanil 0.3 microgram
Ropivacaine and sufentanilDrug
Ropivacaine 0.125% plus sufentanil 0.4 microgram
Ropivacaine and sufentanilDrug
Ropivacaine 0.125% plus sufentanil 0.5 microgram
Ropivacaine and sufentanilDrug
Ropivacaine 0.0625% plus sufentanil 0.4 microgram
Ropivacaine and sufentanilDrug
Ropivacaine 0.1875% plus sufentanil 0.4 microgram
Ropivacaine and sufentanilDrug
Ropivacaine 0.25% plus sufentanil 0.4 microgram
Primary outcomes
What the sponsor says the trial is designed to measure.
- Neurobehavior evaluation with the Assessment of Preterm Infants' Behavior (APIB)Time frame: Immediate after birth (0 min)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Affiliated Nanjing Maternity and Child Health Care Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.